Image of Rachel Spruce

Dr Rachel Spruce

Industry Partnerships and Commercialisation Executive, Medicine

Rachel holds a PhD in Molecular Biology and Oncology and has over 10 years of experience working as an academic in a University setting. Rachel’s academic background is combined with formal training and experience in technology transfer to support the Faculty of Medicine to assess research discoveries for commercial potential and advance these technologies through to market adoption.

Rachel’s role is focused on supporting access to translational funds, collaboration with industry, intellectual property protection, marketing, licensing or spin out.

Rachel 's portfolio

Treatment of Tissue Fibrosis

Treatment of Tissue Fibrosis

, ,

Itaconate and itaconate analogues capable of inhibiting succinate dehydrogenase can be used to treat or prevent tissue fibrosis. Find out more

HKMT Inhibitors

HKMT Inhibitors

,

Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington's disease, viral conditions such as HIV, and cancers Find out more

Machine learning tool stratifying early and late Alzheimer’s disease (ApV)

Machine learning tool stratifying early and late Alzheimer’s disease (ApV)

, ,

A tool for predicting Alzheimer’s Disease with greater accuracy than conventional methods. Find out more

Novel apoptosis marker

Novel apoptosis marker

,

A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging. Find out more

Two-gene signature diagnostic test for differentiating between viral and bacterial infections in children

Two-gene signature diagnostic test for differentiating between viral and bacterial infections in children

,

A simple, whole blood 2-gene expression signature that distinguishes bacterial infection from both viral infection and childhood inflammatory diseases. Find out more

Octreotate Radioligand for Imaging Neuroendocrine Tumors

Octreotate Radioligand for Imaging Neuroendocrine Tumors

,

18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs). Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Sign up now
Loading...